Adenosine A1R/A3R Agonist AST-004 Reduces Brain Infarction in Mouse and Rat Models of Acute Ischemic Stroke

• Published in: bioRxiv
• Main Authors: Fisher, Elizabeth S, Chen, Yanan, Sifuentes, Mikaela M, Stubblefield, Jeremy J, Lozano, Damian, Holstein, Deborah M, Ren, Jingmei, Derosa, Nicholas, Chen, Tsung-Pei, Nickel, Gerard, Liston, Theodore E, Lechleiter, James D
• Format: Paper
• Language: English
• Published: Cold Spring Harbor Cold Spring Harbor Laboratory Press 17.03.2022
• Subjects: Adenosine; Agonists; Animal models; Cerebral blood flow; Cerebral infarction; Ischemia; Mitochondria; mRNA; Pharmaceutical industry; Stroke; Traumatic brain injury
• DOI: 10.1101/2022.03.14.484307

Acute ischemic stroke (AIS) is the second leading cause of death globally. No Food and Drug Administration (FDA) approved therapies exist targeting cerebroprotection following stroke. Our group recently reported significant cerebroprotection with the adenosine A1/A3 receptor agonist, AST-004, in a transient stroke model in non-human primates (NHP) and in a preclinical mouse model of traumatic brain injury (TBI). However, the specific receptor pathway activated was only inferred based on in vitro binding studies. The current study investigated the underlying mechanism of AST-004 cerebroprotection in two independent models of AIS: permanent photothrombotic stroke in mice and transient middle cerebral artery occlusion (MCAO) in rats. AST-004 treatments across a range of doses were cerebroprotective and efficacy could be blocked by A3R antagonism, indicating a mechanism of action that does not require A1R agonism. The high affinity A3R agonist MRS5698 was also cerebroprotective following stroke, but not the A3R agonist Cl-IB-MECA under our experimental conditions. AST-004 efficacy was blocked by the astrocyte specific mitochondrial toxin fluoroacetate, confirming an underlying mechanism of cerebroprotection dependent on astrocyte mitochondrial metabolism. An increase in A3R mRNA levels following stroke suggested an intrinsic cerebroprotective response that was mediated by A3R signaling. Together, these studies confirm certain A3R agonists, such as AST-004, are promising new therapeutics for the treatment of AIS. Competing Interest Statement Astrocyte Pharmaceuticals, a privately held pharmaceutical company, has the exclusive use of patent rights for AST-004 for development and commercialization of its use to treat brain injuries such as stroke. Dr. Lechleiter is a co-founder of Astrocyte Pharmaceuticals and is currently a scientific advisor. Dr. Liston is Vice President of Research at Astrocyte Pharmaceuticals.